Your browser doesn't support javascript.
loading
Efficacy of a home discharge care bundle after acute exacerbation of COPD.
Cousse, Stéphanie; Gillibert, André; Salaün, Mathieu; Thiberville, Luc; Cuvelier, Antoine; Patout, Maxime.
Afiliación
  • Cousse S; Pulmonary, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital, Rouen, France, maxime.patout@chu-rouen.fr.
  • Gillibert A; Department of Biostatistics, Rouen University Hospital, Rouen, France.
  • Salaün M; Pulmonary, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital, Rouen, France, maxime.patout@chu-rouen.fr.
  • Thiberville L; Normandy University, UNIROUEN, CIC INSERM 1404, Rouen, France.
  • Cuvelier A; Pulmonary, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital, Rouen, France, maxime.patout@chu-rouen.fr.
  • Patout M; Normandy University, UNIROUEN, CIC INSERM 1404, Rouen, France.
Article en En | MEDLINE | ID: mdl-30774326
PURPOSE: Acute exacerbations of COPD (AECOPD) are frequent and associated with a poor prognosis. A home discharge care bundle, the PRADO-BPCO program, has been set up by the French National Health System in order to reduce readmission rate after hospitalization for AECOPD. This program includes early consultations by the general practitioner, a nurse, and a physiotherapist after discharge. The aim of our study was to evaluate the effect of the PRADO-BPCO program on the 28-days readmission rate of COPD patients after hospitalization for AECOPD. PATIENTS AND METHODS: This was a retrospective cohort study including all patients admitted for AECOPD in our center between November 2015 and January 2017. The readmission or death rate at 28 days after hospitalization for AECOPD was compared between patients included in the PRADO-BPCO program and patients with standard care after discharge. Inclusion in the program was decided by the physician in charge of the patient. RESULTS: A total of 62 patients were included in the PRADO-BPCO group and 202 in the control group. At baseline, patients in the PRADO group had a more severe COPD disease and more severe exacerbations than the control group and mean inpatient stay was shorter in the PRADO group: 8.6±4.3 vs 10.4±7.4 days (P=0.034). Readmission or death rate at 28 days was similar between groups: 10 (16.1%) in the PRADO group vs 30 (14.9%) in the control group (P=0.81). Ninety-days readmission or death rate and overall survival were similar in the two groups. CONCLUSION: In our center, despite more severe COPD and a shorter hospitalization time, the PRADO-BPCO program failed to prove a benefit on the 28 days readmission or death rate when compared with standard care.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Alta del Paciente / Enfermedad Pulmonar Obstructiva Crónica / Paquetes de Atención al Paciente / Servicios de Atención de Salud a Domicilio Tipo de estudio: Diagnostic_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Alta del Paciente / Enfermedad Pulmonar Obstructiva Crónica / Paquetes de Atención al Paciente / Servicios de Atención de Salud a Domicilio Tipo de estudio: Diagnostic_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Año: 2019 Tipo del documento: Article